FDA Grants Abemaciclib Breakthrough Status for Refractory Breast Cancer

cancer alternative medicine 1 Minute

The FDA has granted the CDK4/6 inhibitor abemaciclib a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor-positive advanced breast cancer. http://www.onclive.com/web-exclusives/fda-grants-abemaciclib-breakthrough-status-for-refractory-breast-cancer

http://pharminent.com/2015/10/08/fda-grants-abemaciclib-breakthrough-status-for-refractory-breast-cancer/

Published by Homer LIM, MD

An Integrative doctor specializing in cancer therapies emphasizing on orthomolecular therapies, acupuncture, homeopathy, energy medicine. I do online medical consultation thru skype, facetime or mobile phone, should you wish to seek more medical information.

Published

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s